NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

慢性腎臟病:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Chronic Kidney Disease - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024244
出版日期 內容資訊 英文 235 Pages
商品交期: 3-5個工作天內
價格
慢性腎臟病:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Chronic Kidney Disease - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 235 Pages
簡介

本報告提供慢性腎臟病市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病概要與流行病學研究

第4章 慢性腎臟病的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 慢性腎臟病的交易趨勢

第7章 慢性腎臟病的開發平台藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH011

GervanoRA's pipeline analysis and opportunity assessment report "Chronic Kidney Disease - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Chronic Kidney Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chronic Kidney Disease drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Chronic Kidney Disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Chronic Kidney Disease drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Chronic Kidney Disease historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Chronic Kidney Disease Market (2020) and the Forecasted Chronic Kidney Disease Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Chronic Kidney Disease Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Chronic Kidney Disease Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Chronic Kidney Disease Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: CHRONIC KIDNEY DISEASE CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF CHRONIC KIDNEY DISEASE COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF CHRONIC KIDNEY DISEASE PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: CLASSIFICATION OF CKD USING GFR AND ACR CATEGORIES
  • TABLE 03: RECOMMENDATIONS PROVIDED BY AMERICAN COLLEGE OF PHYSICIANS
  • TABLE 04: CKD EPIDEMIOLOGY (2020), FORECAST (2021-2030) IN MILLIONS
  • TABLE 05: CKD FINANCING ACTIVITY IN $M
  • TABLE 06: MAJOR COLLABORATIVE AGREEMENTS IN CKD THERAPEUTIC AREA
  • TABLE 07: MAJOR LICENSING AGREEMENTS IN CKD THERAPEUTIC AREA
  • TABLE 08: MAJOR MERGERS AND PARTNERSHIPS IN CKD THERAPEUTIC AREA
  • TABLE 09: PHASE 3 MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 10: PHASE 2 MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 11: PHASE 1 MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 12: PRECLINICAL MOLECULES IN THE CKD DRUG PIPELINE
  • TABLE 13: CKD DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
  • TABLE 14: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY PIPELINE EVENTS, 2020-2030
  • FIGURE 02: CKD EPIDEMIOLOGY (2020), FORECAST (2021-2030) IN MILLIONS
  • FIGURE 03: OVERALL DEALS ACTIVITY IN CKD THERAPEUTIC AREA
  • FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
  • FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 06: CKD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 07: CKD DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 08: CKD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
  • FIGURE 09: CKD DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 10: CKD DRUG PIPELINE ANALYSIS BY DRUG CLASS